Oxidant resistant apolipoprotein A-1 and mimetic peptides
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-014/775
A61K-031/22
A61K-031/366
A61K-031/40
A61K-038/17
A61K-038/00
출원번호
US-0967046
(2013-08-14)
등록번호
US-9051393
(2015-06-09)
발명자
/ 주소
Smith, Jonathan D.
Hazen, Stanley L.
출원인 / 주소
The Cleveland Clinic Foundation
대리인 / 주소
Honigman Miller Schwartz and Cohn LLP
인용정보
피인용 횟수 :
1인용 특허 :
8
초록▼
A method of ameliorating one or more symptoms of an inflammatory condition in a subject comprises the step of administering to the subject a therapeutically effective amount of a polypeptide that is capable promoting cholesterol efflux from lipid loaded cells, the polypeptide consisting of the amino
A method of ameliorating one or more symptoms of an inflammatory condition in a subject comprises the step of administering to the subject a therapeutically effective amount of a polypeptide that is capable promoting cholesterol efflux from lipid loaded cells, the polypeptide consisting of the amino acid sequence of SEQ ID NO:1, in which each X in SEQ ID NO:1 is a phenylalanine amino acid.
대표청구항▼
1. A method of ameliorating one or more symptoms of an inflammatory condition in a subject comprising: administering to the subject a therapeutically effective amount of a polypeptide that is capable of promoting cholesterol efflux from lipid loaded cells, the polypeptide consisting of the amino aci
1. A method of ameliorating one or more symptoms of an inflammatory condition in a subject comprising: administering to the subject a therapeutically effective amount of a polypeptide that is capable of promoting cholesterol efflux from lipid loaded cells, the polypeptide consisting of the amino acid sequence of SEQ ED NO:1, in which each X in SEQ ID NO:1 is a phenylalanine amino acid. 2. The method of claim 1, wherein the inflammatory condition is a recurrent inflammatory condition. 3. The method of claim 2, wherein the recurrent inflammatory condition is an autoimmune disease. 4. The method of claim 3, wherein the autoimmune disease is rheumatoid arthritis. 5. The method of claim 1, comprising the step of administering a statin to the subject. 6. The method of claim 1, wherein the polypeptide is resistant to at least one of oxidation by myeloperoxidase (MPO), oxidation by nitrogen dioxide, oxidation by peroxynitrite (ONOO−), oxidation by peroxycarboxynitrite (ONOCO2−), or oxidation by a product formed when ONOO− acts in presence of CO2 or HCO3− in buffer. 7. The method of claim 1, wherein the polypeptide is a purified polypeptide. 8. The method of claim 1, wherein the polypeptide is a recombinant polypeptide. 9. The method of claim 8, wherein the recombinant polypeptide is produced in bacteria, yeast, plant, insect, avian, or mammalian cells. 10. A method of ameliorating one or more symptoms of an inflammatory condition in a subject, the method comprising the step of administering a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide and a pharmaceutically acceptable excipient, wherein the polypeptide consists of the amino acid sequence of SEQ ID NO:1, in which each X in SEQ ID NO:1 is a phenylalanine amino acid. 11. The method of claim 10, wherein the polypeptide is a purified polypeptide. 12. The method of claim 10, wherein the pharmaceutical composition is formulated for administration to the subject by a route selected from the group consisting of oral administration, nasal administration, rectal administration, intraperitoneal injection, intravascular injection, subcutaneous injection, transcutaneous administration, inhalation administration, and intramuscular injection. 13. The method of claim 12, wherein the pharmaceutical composition is formulated as a unit dosage formulation. 14. The method of claim 13, wherein the pharmaceutical composition is formulated for intravascular administration. 15. The method of claim 13, wherein the pharmaceutical composition comprises a powdered form of the polypeptide and a vehicle. 16. The method of claim 15, wherein the vehicle comprises sterile pyrogen free water, butter, or dextrose solution. 17. The method of claim 15, wherein the powdered form of the polypeptide comprises lyophilized powdered polypeptide. 18. The method of claim 15, wherein the pharmaceutical composition is formulated for intravascular administration, subcutaneous injection, transcutaneous administration, or intramuscular injection. 19. The method of claim 18, wherein the pharmaceutical composition comprises polymeric, hydrophobic materials, or ion exchange resins. 20. The method of claim 10, wherein the inflammatory condition is a recurrent inflammatory condition. 21. The method of claim 20, wherein the recurrent inflammatory condition is an autoimmune disease. 22. The method of claim 21, wherein the autoimmune disease is rheumatoid arthritis. 23. The method of claim 10, wherein the method further comprises administering a statin. 24. The method of claim 23, wherein the statin is: pravastatin, simvastatin, lovastatin, or atorvastatin calcium.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (8)
Queen Cary L. (Los Altos CA) Selick Harold E. (Belmont CA), Humanized immunoglobulins.
Boss Michael A. (Slough GBX) Kenten John H. (High Wycombe GBX) Emtage John S. (High Wycombe GBX) Wood Clive R. (Near Fordingbridge GBX), Multichain polypeptides or proteins and processes for their production.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.